Skip to main content

Immutep Health Care
Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
If you were already registered, log in here.
IMM Announcements on Price Chart

Latest Announcements

Headline Date
Application for quotation of securities - IMM 29 June 2023 at 10:35am
US patent granted for Efti with PD-1 pathway inhibitor 27 June 2023 at 3:00pm
Immutep completes underwritten retail entitlement offer 27 June 2023 at 8:40am
Immutep granted US patent for IMP761 agonist LAG-3 antibody 20 June 2023 at 3:05pm
Change in substantial holding from IFL 16 June 2023 at 5:20pm
Change in substantial holding 13 June 2023 at 7:10pm
Change in substantial holding 13 June 2023 at 8:35am
Becoming a substantial holder 9 June 2023 at 3:25pm
Cleansing Notice 8 June 2023 at 11:20am
Application for quotation of securities - IMM 8 June 2023 at 10:45am
Immutep letter to ineligible shareholders 6 June 2023 at 9:05am
Immutep retail entitlement offer booklet 6 June 2023 at 8:35am
Positive final data in 2nd line head and neck cancer at ASCO 5 June 2023 at 9:05am
Immutep completes institutional pro-rata offer & placement 2 June 2023 at 9:25am
Change in substantial holding 1 June 2023 at 8:50am
Cleansing Notice 31 May 2023 at 11:15am
Proposed issue of securities - IMM 31 May 2023 at 10:50am
Immutep Capital Raising Presentation 31 May 2023 at 10:35am
A$80 million fully underwritten equity raising 31 May 2023 at 10:05am
Trading Halt 31 May 2023 at 9:50am
Charles River Laboratories to run IMP761 Toxicology Study 29 May 2023 at 8:45am
Publication of Abstracts for ASCO 2023 Annual Meeting 26 May 2023 at 8:45am
1st patient dosed in AIPAC-003 ph2/3 breast cancer trial 25 May 2023 at 8:40am
Promising New Data in 1st line NSCLC from INSIGHT-003 Trial 24 May 2023 at 9:25am
Excellent initial Overall Survival Benefit in 1st line NSCLC 17 May 2023 at 9:30am
FDA supportive of Efti registrational trial in lung cancer 16 May 2023 at 8:45am
Change of Director's Interest Notice - R Howard 2 May 2023 at 8:40am
Approval to start Efti & Bavencio trial in urothelial cancer 1 May 2023 at 8:35am
Immutep Quarterly Activities Report and Appendix 4C 27 April 2023 at 8:25am
Immutep to announce new TACTI-002 data at ASCO 2023 27 April 2023 at 8:25am
Immutep appoints Dr Florian Vogl as Chief Medical Officer 26 April 2023 at 9:15am
Response to ASX Aware Query 18 April 2023 at 10:45am
Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma 17 April 2023 at 8:45am
Notification of cessation of securities - IMM 11 April 2023 at 10:20am
Appendix 3Z - Lucy Turnbull 11 April 2023 at 9:35am
Appendix 3X - Lis Boyce 11 April 2023 at 9:10am
Immutep Announces Changes to the Board 11 April 2023 at 9:00am
Positive Final Data in 2nd Line Metastatic NSCLC Patients 31 March 2023 at 6:15pm
Change in substantial holding 31 March 2023 at 8:45am
Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC 30 March 2023 at 10:25am
Abstract accepted for ESMO's European Lung Cancer Congress 23 March 2023 at 11:50am
Initiation of Ph 2/3 Trial for Metastatic Breast Cancer 14 March 2023 at 8:35am
Half Yearly Report and Accounts 24 February 2023 at 7:20pm
Enrolment Target Reached for INSIGHT-003 Trial in NSCLC 6 February 2023 at 9:10am
Immutep Quarterly Activities Report and Appendix 4C 30 January 2023 at 8:55am
Notification of cessation of securities - IMM 6 January 2023 at 4:40pm
TACTI-003 trial 50% enrolment milestone has been achieved 4 January 2023 at 8:45am
Update on MBC trial design following successful FDA meeting 23 December 2022 at 1:20pm
Change of Director's Interest Notice L Turnbull 22 December 2022 at 4:20pm
Change of Director's Interest Notice - P Meyers 22 December 2022 at 4:20pm
If you were already registered, log in here.